Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF.

[1]  I. Piña,et al.  PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial. , 2020, American heart journal.

[2]  P. Ponikowski,et al.  Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.

[3]  Christopher L. Roy,et al.  2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2019, Journal of the American College of Cardiology.

[4]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[5]  Akshay S. Desai,et al.  Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. , 2019, Circulation. Heart failure.

[6]  S. Solomon,et al.  Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction , 2019, JAMA network open.

[7]  Akshay S. Desai,et al.  Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. , 2019, Circulation.

[8]  I. Piña,et al.  Abstract 252: PredischaRge Initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial , 2019, Circulation: Cardiovascular Quality and Outcomes.

[9]  Akshay S. Desai,et al.  Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. , 2019, JACC. Heart failure.

[10]  G. David,et al.  The effect of predictive analytics-driven interventions on healthcare utilization. , 2019, Journal of health economics.

[11]  E. Braunwald,et al.  Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.

[12]  M. Vaduganathan,et al.  Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. , 2019, JACC. Heart failure.

[13]  R. Califf,et al.  Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points: From the ASCEND-HF Trial , 2018, Circulation. Cardiovascular quality and outcomes.

[14]  Akshay S. Desai,et al.  Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial , 2018, JAMA cardiology.

[15]  C. Izumi,et al.  Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics? , 2018, European heart journal.

[16]  Roland A Matsouaka,et al.  Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. , 2017, Journal of the American College of Cardiology.

[17]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.

[18]  Akshay S. Desai,et al.  Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. , 2016, Journal of the American College of Cardiology.

[19]  M. Vaduganathan,et al.  The vulnerable phase after hospitalization for heart failure , 2015, Nature Reviews Cardiology.

[20]  Akshay S. Desai,et al.  Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction , 2014, Circulation. Heart failure.

[21]  Akshay S. Desai,et al.  Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction , 2013, Circulation. Heart failure.

[22]  M. Vaduganathan,et al.  Thirty-day readmissions: the clock is ticking. , 2013, JAMA.

[23]  Karl Swedberg,et al.  Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.

[24]  V. Hasselblad,et al.  Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.

[25]  Zhiliang Ying,et al.  Semiparametric regression for the mean and rate functions of recurrent events , 2000 .